Skip to main content
PMC home page
Gut logoLink to Gut
. 2003 Jun;52(Suppl 4):iv23–iv29. doi: 10.1136/gut.52.suppl_4.iv23

18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies

B Chin, R Wahl
PMCID: PMC1867761  PMID: 12746265

Abstract

Positron emission tomography with 18F-fluoro-2-deoxyglucose is an imaging technology that is demonstrating increasing utility in the evaluation of gastrointestinal malignancies.

Full Text

The Full Text of this article is available as a PDF (163.3 KB).

Figure 1.

Figure 1

Open in a new tab

A 45 year old woman with stage III colorectal cancer presented with rising CEA after primary tumour resection. (Top row) Coronal and (bottom row) transaxial tomographic slices. (Left) CT was interpreted as negative for recurrence. (Centre) FDG PET shows intense activity at the anastamosis compatible with tumour recurrence. This was subsequently verified after surgery. (Right) Fusion of PET and CT localises the abnormality.

Figure 2.

Figure 2

Open in a new tab

A 57 year old man with oesophageal cancer and clinical stage T3N1 presented for staging evaluation. (Left) Anterior coronal and (right) posterior coronal FDG PET show multiple foci of intense metabolic activity compatible with widespread metastases. CT scan confirmed many of these sites, but was unable to detect spread to lymph nodes and distant soft tissue site.

Figure 3.

Figure 3

Open in a new tab

A 43 year old woman with pancreatic cancer presented for evaluation of lung nodules. (Top row) Coronal and (bottom row) transaxial tomographic slices. (Left) CT shows the mass in the abdomen, but is unable to characterise the hilar lymph node. (Centre) FDG PET shows intense activity in the abdominal mass and increased uptake in the hilar lymph node (additional lung abnormalities not shown) compatible with local recurrence and distant metastases. Clinical follow up of lung abnormalities was consistent with metastases. (Right) Fusion of PET and CT localises the abnormalities.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abdel-Nabi H., Doerr R. J., Lamonica D. M., Cronin V. R., Galantowicz P. J., Carbone G. M., Spaulding M. B. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology. 1998 Mar;206(3):755–760. doi: 10.1148/radiology.206.3.9494497. [DOI] [PubMed] [Google Scholar]
  2. Arulampalam T. H., Costa D. C., Bomanji J. B., Ell P. J. The clinical application of positron emission tomography to colorectal cancer management. Q J Nucl Med. 2001 Sep;45(3):215–230. [PubMed] [Google Scholar]
  3. Arulampalam T., Costa D., Visvikis D., Boulos P., Taylor I., Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med. 2001 Oct 20;28(12):1758–1765. doi: 10.1007/s002590100646. [DOI] [PubMed] [Google Scholar]
  4. Bares R., Klever P., Hauptmann S., Hellwig D., Fass J., Cremerius U., Schumpelick V., Mittermayer C., Büll U. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology. 1994 Jul;192(1):79–86. doi: 10.1148/radiology.192.1.8208970. [DOI] [PubMed] [Google Scholar]
  5. Block M. I., Patterson G. A., Sundaresan R. S., Bailey M. S., Flanagan F. L., Dehdashti F., Siegel B. A., Cooper J. D. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg. 1997 Sep;64(3):770–777. doi: 10.1016/s0003-4975(97)00619-x. [DOI] [PubMed] [Google Scholar]
  6. Bombardieri E., Maccauro M., De Deckere E., Savelli G., Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol. 2001;12 (Suppl 2):S51–S61. doi: 10.1093/annonc/12.suppl_2.s51. [DOI] [PubMed] [Google Scholar]
  7. Brücher B. L., Weber W., Bauer M., Fink U., Avril N., Stein H. J., Werner M., Zimmerman F., Siewert J. R., Schwaiger M. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001 Mar;233(3):300–309. doi: 10.1097/00000658-200103000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Choi J. Y., Lee K. H., Shim Y. M., Lee K. S., Kim J. J., Kim S. E., Kim B. T. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med. 2000 May;41(5):808–815. [PubMed] [Google Scholar]
  9. De Potter T., Flamen P., Van Cutsem E., Penninckx F., Filez L., Bormans G., Maes A., Mortelmans L. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging. 2002 Feb 23;29(4):525–529. doi: 10.1007/s00259-001-0743-8. [DOI] [PubMed] [Google Scholar]
  10. Delbeke D., Martin W. H., Sandler M. P., Chapman W. C., Wright J. K., Jr, Pinson C. W. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998 May;133(5):510–516. doi: 10.1001/archsurg.133.5.510. [DOI] [PubMed] [Google Scholar]
  11. Delbeke D., Rose D. M., Chapman W. C., Pinson C. W., Wright J. K., Beauchamp R. D., Shyr Y., Leach S. D. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999 Nov;40(11):1784–1791. [PubMed] [Google Scholar]
  12. Delbeke D., Vitola J. V., Sandler M. P., Arildsen R. C., Powers T. A., Wright J. K., Jr, Chapman W. C., Pinson C. W. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997 Aug;38(8):1196–1201. [PubMed] [Google Scholar]
  13. Diederichs C. G., Staib L., Glatting G., Beger H. G., Reske S. N. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998 Jun;39(6):1030–1033. [PubMed] [Google Scholar]
  14. Drenth J. P., Nagengast F. M., Oyen W. J. Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med. 2001 Oct 19;28(12):1766–1769. doi: 10.1007/s002590100645. [DOI] [PubMed] [Google Scholar]
  15. Findlay M., Young H., Cunningham D., Iveson A., Cronin B., Hickish T., Pratt B., Husband J., Flower M., Ott R. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996 Mar;14(3):700–708. doi: 10.1200/JCO.1996.14.3.700. [DOI] [PubMed] [Google Scholar]
  16. Flamen P., Hoekstra O. S., Homans F., Van Cutsem E., Maes A., Stroobants S., Peeters M., Penninckx F., Filez L., Bleichrodt R. P. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001 May;37(7):862–869. doi: 10.1016/s0959-8049(01)00049-1. [DOI] [PubMed] [Google Scholar]
  17. Flamen P., Lerut A., Van Cutsem E., De Wever W., Peeters M., Stroobants S., Dupont P., Bormans G., Hiele M., De Leyn P. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000 Sep 15;18(18):3202–3210. doi: 10.1200/JCO.2000.18.18.3202. [DOI] [PubMed] [Google Scholar]
  18. Flamen P., Stroobants S., Van Cutsem E., Dupont P., Bormans G., De Vadder N., Penninckx F., Van Hoe L., Mortelmans L. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol. 1999 Mar;17(3):894–901. doi: 10.1200/JCO.1999.17.3.894. [DOI] [PubMed] [Google Scholar]
  19. Flamen Patrick. Positron emission tomography in colorectal cancer. Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):237–251. doi: 10.1053/bega.2001.0283. [DOI] [PubMed] [Google Scholar]
  20. Flanagan F. L., Dehdashti F., Ogunbiyi O. A., Kodner I. J., Siegel B. A. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg. 1998 Mar;227(3):319–323. doi: 10.1097/00000658-199803000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Flanagan F. L., Dehdashti F., Siegel B. A., Trask D. D., Sundaresan S. R., Patterson G. A., Cooper J. D. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997 Feb;168(2):417–424. doi: 10.2214/ajr.168.2.9016218. [DOI] [PubMed] [Google Scholar]
  22. Fong Y., Saldinger P. F., Akhurst T., Macapinlac H., Yeung H., Finn R. D., Cohen A., Kemeny N., Blumgart L. H., Larson S. M. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg. 1999 Oct;178(4):282–287. doi: 10.1016/s0002-9610(99)00187-7. [DOI] [PubMed] [Google Scholar]
  23. Friess H., Langhans J., Ebert M., Beger H. G., Stollfuss J., Reske S. N., Büchler M. W. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut. 1995 May;36(5):771–777. doi: 10.1136/gut.36.5.771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Fritscher-Ravens A., Bohuslavizki K. H., Broering D. C., Jenicke L., Schäfer H., Buchert R., Rogiers X., Clausen M. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun. 2001 Dec;22(12):1277–1285. doi: 10.1097/00006231-200112000-00002. [DOI] [PubMed] [Google Scholar]
  25. Fröhlich A., Diederichs C. G., Staib L., Vogel J., Beger H. G., Reske S. N. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med. 1999 Feb;40(2):250–255. [PubMed] [Google Scholar]
  26. Guillem J. G., Puig-La Calle J., Jr, Akhurst T., Tickoo S., Ruo L., Minsky B. D., Gollub M. J., Klimstra D. S., Mazumdar M., Paty P. B. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000 Jan;43(1):18–24. doi: 10.1007/BF02237238. [DOI] [PubMed] [Google Scholar]
  27. Haberkorn U., Strauss L. G., Dimitrakopoulou A., Engenhart R., Oberdorfer F., Ostertag H., Romahn J., van Kaick G. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med. 1991 Aug;32(8):1485–1490. [PubMed] [Google Scholar]
  28. Higashi Tatsuya, Saga Tsuneo, Nakamoto Yuji, Ishimori Takayoshi, Mamede Marcelo H., Wada Michihiko, Doi Ryuichiro, Hosotani Ryo, Imamura Masayuki, Konishi Junji. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002 Feb;43(2):173–180. [PubMed] [Google Scholar]
  29. Ho C. L., Dehdashti F., Griffeth L. K., Buse P. E., Balfe D. M., Siegel B. A. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr. 1996 May-Jun;20(3):363–369. doi: 10.1097/00004728-199605000-00006. [DOI] [PubMed] [Google Scholar]
  30. Huebner R. H., Park K. C., Shepherd J. E., Schwimmer J., Czernin J., Phelps M. E., Gambhir S. S. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000 Jul;41(7):1177–1189. [PubMed] [Google Scholar]
  31. Inokuma T., Tamaki N., Torizuka T., Fujita T., Magata Y., Yonekura Y., Ohshio G., Imamura M., Konishi J. Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med. 1995 Feb;36(2):229–235. [PubMed] [Google Scholar]
  32. Inokuma T., Tamaki N., Torizuka T., Magata Y., Fujii M., Yonekura Y., Kajiyama T., Ohshio G., Imamura M., Konishi J. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology. 1995 May;195(2):345–352. doi: 10.1148/radiology.195.2.7724751. [DOI] [PubMed] [Google Scholar]
  33. Jadvar H., Fischman A. J. Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging. 2001 May-Jun;26(3):254–259. doi: 10.1007/s002610000159. [DOI] [PubMed] [Google Scholar]
  34. Kalff Victor, Hicks Rodney J., Ware Robert E., Hogg Annette, Binns David, McKenzie Allan F. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med. 2002 Apr;43(4):492–499. [PubMed] [Google Scholar]
  35. Kato Hiroyuki, Kuwano Hiroyuki, Nakajima Masanobu, Miyazaki Tatsuya, Yoshikawa Minako, Ojima Hitoshi, Tsukada Katsuhiko, Oriuchi Noboru, Inoue Tomio, Endo Keigo. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 2002 Feb 15;94(4):921–928. [PubMed] [Google Scholar]
  36. Kawamura T., Kusakabe T., Sugino T., Watanabe K., Fukuda T., Nashimoto A., Honma K., Suzuki T. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001 Aug 1;92(3):634–641. doi: 10.1002/1097-0142(20010801)92:3<634::aid-cncr1364>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  37. Keiding S., Hansen S. B., Rasmussen H. H., Gee A., Kruse A., Roelsgaard K., Tage-Jensen U., Dahlerup J. F. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology. 1998 Sep;28(3):700–706. doi: 10.1002/hep.510280316. [DOI] [PubMed] [Google Scholar]
  38. Keogan M. T., Tyler D., Clark L., Branch M. S., McDermott V. G., DeLong D. M., Coleman R. E. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol. 1998 Dec;171(6):1565–1570. doi: 10.2214/ajr.171.6.9843289. [DOI] [PubMed] [Google Scholar]
  39. Khan M. A., Combs C. S., Brunt E. M., Lowe V. J., Wolverson M. K., Solomon H., Collins B. T., Di Bisceglie A. M. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000 May;32(5):792–797. doi: 10.1016/s0168-8278(00)80248-2. [DOI] [PubMed] [Google Scholar]
  40. Kluge R., Schmidt F., Caca K., Barthel H., Hesse S., Georgi P., Seese A., Huster D., Berr F. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001 May;33(5):1029–1035. doi: 10.1053/jhep.2001.23912. [DOI] [PubMed] [Google Scholar]
  41. Kole A. C., Plukker J. T., Nieweg O. E., Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer. 1998 Aug;78(4):521–527. doi: 10.1038/bjc.1998.526. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Libutti S. K., Alexander H. R., Jr, Choyke P., Bartlett D. L., Bacharach S. L., Whatley M., Jousse F., Eckelman W. C., Kranda K., Neumann R. D. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol. 2001 Dec;8(10):779–786. doi: 10.1007/s10434-001-0779-9. [DOI] [PubMed] [Google Scholar]
  43. Lonneux Max, Reffad Abdel-Malek, Detry Roger, Kartheuser Alex, Gigot Jean-François, Pauwels Stanislas. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging. 2002 Apr 13;29(7):915–921. doi: 10.1007/s00259-002-0802-9. [DOI] [PubMed] [Google Scholar]
  44. Maisey N. R., Webb A., Flux G. D., Padhani A., Cunningham D. C., Ott R. J., Norman A. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer. 2000 Aug;83(3):287–293. doi: 10.1054/bjoc.2000.1166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Meta J., Seltzer M., Schiepers C., Silverman D. H., Ariannejad M., Gambhir S. S., Phelps M. E., Valk P., Czernin J. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med. 2001 Apr;42(4):586–590. [PubMed] [Google Scholar]
  46. Nagata Y., Yamamoto K., Hiraoka M., Abe M., Takahashi M., Akuta K., Nishimura Y., Jo S., Masunaga S., Kubo S. Monitoring liver tumor therapy with [18F]FDG positron emission tomography. J Comput Assist Tomogr. 1990 May-Jun;14(3):370–374. [PubMed] [Google Scholar]
  47. Nakamoto Y., Higashi T., Sakahara H., Tamaki N., Kogire M., Doi R., Hosotani R., Imamura M., Konishi J. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000 Dec 15;89(12):2547–2554. doi: 10.1002/1097-0142(20001215)89:12<2547::aid-cncr5>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  48. Nitzsche Egbert U., Hoegerle Stefan, Mix Michael, Brink Ingo, Otte Andreas, Moser Ernst, Imdahl Andreas. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis? Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):237–242. doi: 10.1007/s00259-001-0697-x. [DOI] [PubMed] [Google Scholar]
  49. Park K. C., Schwimmer J., Shepherd J. E., Phelps M. E., Czernin J. R., Schiepers C., Gambhir S. S. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg. 2001 Mar;233(3):310–319. doi: 10.1097/00000658-200103000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Reske S. N., Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med. 2001 Nov;28(11):1707–1723. doi: 10.1007/s002590100626. [DOI] [PubMed] [Google Scholar]
  51. Rose D. M., Delbeke D., Beauchamp R. D., Chapman W. C., Sandler M. P., Sharp K. W., Richards W. O., Wright J. K., Frexes M. E., Pinson C. W. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg. 1999 May;229(5):729–738. doi: 10.1097/00000658-199905000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Ruers T. J. M., Langenhoff B. S., Neeleman N., Jager G. J., Strijk S., Wobbes Th, Corstens F. H. M., Oyen W. J. G. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002 Jan 15;20(2):388–395. doi: 10.1200/JCO.2002.20.2.388. [DOI] [PubMed] [Google Scholar]
  53. Ruers T., Bleichrodt R. P. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 2002 May;38(7):1023–1033. doi: 10.1016/s0959-8049(02)00059-x. [DOI] [PubMed] [Google Scholar]
  54. Schiepers C., Haustermans K., Geboes K., Filez L., Bormans G., Penninckx F. The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. Cancer. 1999 Feb 15;85(4):803–811. doi: 10.1002/(sici)1097-0142(19990215)85:4<803::aid-cncr7>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  55. Sendler A., Avril N., Helmberger H., Stollfuss J., Weber W., Bengel F., Schwaiger M., Roder J. D., Siewert J. R. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg. 2000 Sep;24(9):1121–1129. doi: 10.1007/s002680010182. [DOI] [PubMed] [Google Scholar]
  56. Shiomi S., Nishiguchi S., Ishizu H., Iwata Y., Sasaki N., Tamori A., Habu D., Takeda T., Kubo S., Ochi H. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol. 2001 Jun;96(6):1877–1880. doi: 10.1111/j.1572-0241.2001.03888.x. [DOI] [PubMed] [Google Scholar]
  57. Shreve P. D. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med. 1998 Mar;25(3):259–264. doi: 10.1007/s002590050226. [DOI] [PubMed] [Google Scholar]
  58. Sperti C., Pasquali C., Chierichetti F., Liessi G., Ferlin G., Pedrazzoli S. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg. 2001 Nov;234(5):675–680. doi: 10.1097/00000658-200111000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Staib L., Schirrmeister H., Reske S. N., Beger H. G. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg. 2000 Jul;180(1):1–5. doi: 10.1016/s0002-9610(00)00406-2. [DOI] [PubMed] [Google Scholar]
  60. Stollfuss J. C., Glatting G., Friess H., Kocher F., Berger H. G., Reske S. N. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology. 1995 May;195(2):339–344. doi: 10.1148/radiology.195.2.7724750. [DOI] [PubMed] [Google Scholar]
  61. Strasberg S. M., Dehdashti F., Siegel B. A., Drebin J. A., Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg. 2001 Mar;233(3):293–299. doi: 10.1097/00000658-200103000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Strasberg Steven M., Siegal Barry A. Survival of patients staged by FDG-PET before resection of hepatic metastases from colorectal cancer. Ann Surg. 2002 Feb;235(2):308–310. doi: 10.1097/00000658-200202000-00022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Topal B., Flamen P., Aerts R., D'Hoore A., Filez L., Van Cutsem E., Mortelmans L., Penninckx F. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol. 2001 Mar;27(2):175–179. doi: 10.1053/ejso.2000.1075. [DOI] [PubMed] [Google Scholar]
  64. Torizuka T., Tamaki N., Inokuma T., Magata Y., Sasayama S., Yonekura Y., Tanaka A., Yamaoka Y., Yamamoto K., Konishi J. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995 Oct;36(10):1811–1817. [PubMed] [Google Scholar]
  65. Torizuka T., Tamaki N., Inokuma T., Magata Y., Yonekura Y., Tanaka A., Yamaoka Y., Yamamoto K., Konishi J. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med. 1994 Dec;35(12):1965–1969. [PubMed] [Google Scholar]
  66. Valk P. E., Abella-Columna E., Haseman M. K., Pounds T. R., Tesar R. D., Myers R. W., Greiss H. B., Hofer G. A. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999 May;134(5):503–513. doi: 10.1001/archsurg.134.5.503. [DOI] [PubMed] [Google Scholar]
  67. Vitola J. V., Delbeke D., Meranze S. G., Mazer M. J., Pinson C. W. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer. 1996 Nov 15;78(10):2216–2222. doi: 10.1002/(sici)1097-0142(19961115)78:10<2216::aid-cncr25>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  68. Weber W. A., Ott K., Becker K., Dittler H. J., Helmberger H., Avril N. E., Meisetschläger G., Busch R., Siewert J. R., Schwaiger M. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001 Jun 15;19(12):3058–3065. doi: 10.1200/JCO.2001.19.12.3058. [DOI] [PubMed] [Google Scholar]
  69. Whiteford M. H., Whiteford H. M., Yee L. F., Ogunbiyi O. A., Dehdashti F., Siegel B. A., Birnbaum E. H., Fleshman J. W., Kodner I. J., Read T. E. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum. 2000 Jun;43(6):759–770. doi: 10.1007/BF02238010. [DOI] [PubMed] [Google Scholar]
  70. Yasuda S., Fujii H., Nakahara T., Nishiumi N., Takahashi W., Ide M., Shohtsu A. 18F-FDG PET detection of colonic adenomas. J Nucl Med. 2001 Jul;42(7):989–992. [PubMed] [Google Scholar]
  71. Zimny M., Bares R., Fass J., Adam G., Cremerius U., Dohmen B., Klever P., Sabri O., Schumpelick V., Buell U. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med. 1997 Jun;24(6):678–682. doi: 10.1007/BF00841409. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES